文献速递临床试验与 GCP真实世界研究与卫生经济

实施研究:在南非和肯尼亚的1型糖尿病患者中开展持续葡萄糖监测设备的两项三臂实用性随机对照试验方案

Implementation research: a protocol for two three-arm pragmatic randomised controlled trials on continuous glucose monitoring devices in people with type 1 diabetes in South Africa and Kenya.
PubMed 文献 · Trials · 2024-05-21

该方案设计为在南非和肯尼亚开展的两项实用性、平行组、开放标签、多中心、三臂、按1:1:1随机对照试验,比较持续或周期性使用持续葡萄糖监测(CGM)设备与标准治疗对1型糖尿病患者血糖控制的影响,主要结局为糖化血红蛋白(HbA1c)较基线的变化。试验注册号为NCT05944731(肯尼亚,2023年7月6日)和NCT05944718(南非,2023年7月13日)。

要点

  • 在南非和肯尼亚的1型糖尿病患者中比较持续或周期性CGM使用与标准治疗。
  • 主要结局为HbA1c较基线的变化,并评估血糖变异、安全性和生活质量等。
  • 试验注册号:NCT05944731(肯尼亚,2023年7月6日)和NCT05944718(南非,2023年7月13日)。

核心结论

  • 该试验旨在填补中低收入国家(特别是南非和肯尼亚)关于CGM设备使用对临床结局影响的大量证据空白,试验结果将为这些国家的政策和治疗决策提供证据。

研究设计与样本

  • 该试验为实用性、平行组、开放标签、多中心、三臂、按1:1:1随机对照试验,比较持续或周期性CGM设备使用与标准治疗。

主要发现

  • 主要目标为评估持续或周期性CGM设备使用对血糖控制的影响,以糖化血红蛋白(HbA1c)较基线的变化衡量。
  • 额外评估包括临床结局(血糖变异、范围内/低于范围/高于范围时间)、安全性(不良事件、住院)、生活质量(EQ-5D、T1D痛苦评分、T1D葡萄糖监测满意度调查)和健康经济学指标(增量成本效果比、质量调整生命年)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Self-monitoring of glucose is an essential component of type 1 diabetes (T1D) management. In recent years, continuous glucose monitoring (CGM) has provided an alternative to daily fingerstick testing for the optimisation of insulin dosing and general glucose management in people with T1D. While studies have been conducted to evaluate the impact of CGM on clinical outcomes in the US, Europe and Australia, there are limited data available for low- and middle-income countries (LMICs) and further empirical evidence is needed to inform policy decision around their use in these countries. METHODS: This trial was designed as a pragmatic, parallel-group, open-label, multicentre, three-arm, randomised (1:1:1) controlled trial of continuous or periodic CGM device use versus standard of care in people with T1D in South Africa and Kenya. The primary objective of this trial will be to assess the impact of continuous or periodic CGM device use on glycaemic control as measured by change from baseline glycosylated haemoglobin (HbA1c). Additional assessments will include clinical outcomes (glucose variation, time in/below/above range), safety (adverse events, hospitalisations), quality of life (EQ-5D, T1D distress score, Glucose Monitoring Satisfaction Survey for T1D), and health economic measures (incremental cost-effectiveness ratios, quality adjusted life years). DISCUSSION: This trial aims to address the substantial evidence gap on the impact of CGM device use on clinical outcomes in LMICs, specifically South Africa and Kenya. The trial results will provide evidence to inform policy and treatment decisions in these countries. TRIAL REGISTRATION: NCT05944731 (Kenya), July 6, 2023; NCT05944718 (South Africa), July 13, 2023.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Marbán-Castro E, Muhwava L, Kamau Y, et al. Implementation research: a protocol for two three-arm pragmatic randomised controlled trials on continuous glucose monitoring devices in people with type 1 diabetes in South Africa and Kenya. Trials. 2024. PMID: 38773658. doi:10.1186/s13063-024-08132-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。